New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
07:10 EDTCNCEConcert expects to 'sufficiently' fund company into FY16
The company said, "Based upon Concertís current operating budget, the company expects that its cash, cash equivalents and investments as of December 31, 2013, together with the net proceeds from the initial public offering, will be sufficient to fund the Company into FY16."
News For CNCE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
09:02 EDTCNCEConcert Pharmaceuticals 500K share Block Trade priced at $12.55
The deal range was $12.42-$12.55. UBS acted as sole book running manager for the offering.
November 12, 2014
08:22 EDTCNCEConcert Pharma to delay initiation of planned CTP-354 Phase 2 clinical trials
Based upon preliminary findings from an ongoing three-month non-clinical study with CTP-354, the company has today announced its decision to delay the initiation of its planned CTP-354 Phase 2 clinical trials. Concert intends to conduct additional non-clinical studies to further characterize CTP-354 and assess its development profile. The Company had previously planned to initiate a Phase 2 program in 2014 in parallel with the ongoing non-clinical evaluation. CTP-354 is being developed as a potential non-sedating treatment for spasticity in patients with spinal cord injury and with multiple sclerosis.
08:21 EDTCNCEConcert Pharmaceuticals reports Q3 EPS (43c), consensus (49c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use